X

Ranitidine (Zantac®) Making a Comeback

By: Mandy Zheng, PharmD Candidate c/o 2024               “Where can I find Zantac?”. From April 2020 to May 2021, the…

eMAR

Dravet’s Syndrome and a Novel Antiepileptic Drug: Cannabidiol (Epidiolex®)

By: Jason Ifeanyi, PharmD Candidate c/o 2022               Epilepsy is a highly prevalent neurological disorder caused by unusual nerve cell…

eMAR

Potentially Life-Threatening Interactions Between Newer Smartphones and ICDs

By: Richa Tamakuwala, PharmD Candidate c/o 2022               There has been a dramatic rise in the number of patients with…

eMAR

A New Approach with an Old Drug: Colchicine and Heart Disease

By: Mathew Fontanez, PharmD Candidate c/o 2022               What place does the familiar gout medication colchicine have in the fight…

eMAR

CAR T-cell therapy for Multiple Myeloma

By: Lyana Sayilar, PharmD Candidate c/o 2022               Multiple myeloma is characterized by an accumulation of abnormal plasma cells in…

eMAR

Antiepileptics in Migraine Prophylaxis

By: Krishna Tamakuwala, PharmD candidate c/o 2023               Migraines are characterized by episodes of head pain that are often throbbing…

eMAR

Drug Information Questions: Vaccines are Drugs Too

By: Aisa Mrkulic, Maria Michael and Svetlana Bachayev, PharmD Candidates c/o 2022               With the surge of Coronavirus Disease 2019…

eMAR

Connecting the Dots: Ankylosing Spondylitis and Heart Disease

By: Jennifer Galvet, PharmD Candidate c/o 2024              Ankylosing spondylitis (AS) is a systemic inflammatory condition that primarily affects a…

eMAR

FDA approves Vibegron (Gemtesa®) for the Treatment of Patients with Symptoms of Overactive Bladder

By: Arya Firoozan, PharmD Candidate c/o 2023              Overactive bladder (OAB) is a condition that causes a sudden and frequent…

eMAR

Correlation of Salt-Intake and Hypertension

By: Jordan Plair, PharmD Candidate c/o 2022 and Marina Beshara, PharmD Candidate c/o 2022              While the focus over the…

eMAR